Doses - MEGESTROL ACETATE
NOTE: Because of the low margin of safety; calculate dosages very carefully. Do not confusemg/lb with mg/kg!Dogs:
For treatment of heartworm disease:
After diagnosis, determine the class (stage) of the disease. Note: The manufacturer providesworksheets that assist in the classification and treatment regime determination. It ishighly recommended to use these treatment records to avoid confusion and documenttherapy.
Class I: 2.5 mg/kg deep IM as directed (lumbar epaxial muscles (L3-L5) twice 24 hoursapart and rest. Use alternating sides with each administration. In 4 months, the regimenmay be repeated.
Class II: 2.5 mg/kg deep IM as directed (lumbar epaxial muscles (L3-L5) twice 24 hoursapart and rest; give symptomatic treatment as required. Use alternating sides with eachadministration. In 4 months, the regimen may be repeated.
Class III: 2.5 mg/kg deep IM as directed (lumbar epaxial muscles (L3-L5). Strict rest andgive all necessary systemic treatment. One month later, give 2.5 mg/kg deep IM as directed (lumbar epaxial muscles (L3-L5) twice 24 hours apart.
Note: Recommended needle size for dogs 10kg or less = 23 gauge 1 inch; 10 kg or morebody weight = 22 gauge 1.5 inch. (Package Insert; Immiticide®¯Merial)
Monitoring Parameters/Client Information - Clinical efficacy and adverse effects. Because ofthe seriousness of the disease and the potential for morbidity and mortality associated with thetreatment, clients should give informed consent before electing to treat.
Dosage Forms/Preparations/FDA Approval Status - Veterinary-Approved Products:
Melarsomine Dihydrochloride Powder for Injection 50 mg/vial; Immiticide® (Merial); (Rx)
Approved for use in dogs.
Reconstitute with 2 ml of the diluent provided (sterile water for injection) with a resultantconcentration of 25 mg/ml. Once reconstituted, the solution should be kept in the originalcontainer and kept refrigerated for up to 24 hours. Do not freeze.
Human-Approved Products: None
Dogs: 
For treatment of heartworm disease: After diagnosis, determine the class (stage) of the disease. Note: The manufacturer providesworksheets that assist in the classification and treatment regime determination. It ishighly recommended to use these treatment records to avoid confusion and documenttherapy.
Class I: 2.5 mg/kg deep IM as directed (lumbar epaxial muscles (L3-L5) twice 24 hoursapart and rest. Use alternating sides with each administration. In 4 months, the regimenmay be repeated.
Class II: 2.5 mg/kg deep IM as directed (lumbar epaxial muscles (L3-L5) twice 24 hoursapart and rest; give symptomatic treatment as required. Use alternating sides with eachadministration. In 4 months, the regimen may be repeated.
Class III: 2.5 mg/kg deep IM as directed (lumbar epaxial muscles (L3-L5). Strict rest andgive all necessary systemic treatment. One month later, give 2.5 mg/kg deep IM as directed (lumbar epaxial muscles (L3-L5) twice 24 hours apart.
Note: Recommended needle size for dogs 10kg or less = 23 gauge 1 inch; 10 kg or morebody weight = 22 gauge 1.5 inch. (Package Insert; Immiticide®¯Merial)
Monitoring Parameters/Client Information - Clinical efficacy and adverse effects. Because ofthe seriousness of the disease and the potential for morbidity and mortality associated with thetreatment, clients should give informed consent before electing to treat.
Dosage Forms/Preparations/FDA Approval Status - Veterinary-Approved Products:
Melarsomine Dihydrochloride Powder for Injection 50 mg/vial; Immiticide® (Merial); (Rx)
Approved for use in dogs.
Reconstitute with 2 ml of the diluent provided (sterile water for injection) with a resultantconcentration of 25 mg/ml. Once reconstituted, the solution should be kept in the originalcontainer and kept refrigerated for up to 24 hours. Do not freeze.
Human-Approved Products: None